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Abstract
Background: Early manifestations of pediatric inflammatory bowel disease (IBD) can be relatively nonspecific. Initial
mucosal biopsies may not be conclusive, delaying the diagnosis until subsequent biopsies demonstrate typical
histologic features of IBD. We hypothesized that certain inflammatory cell types may be utilized as early histologic
indicators of IBD in children.
Methods: A retrospective analysis compared histologic findings from initially inconclusive or negative endoscopic
studies in 22 patients who were subsequently diagnosed with IBD (after diagnostic endoscopy) to those of 20
comparison patients with functional abdominal pain matched for age, gender, and study type. A pediatric pathologist,
blinded to study group, reviewed biopsies for histologic abnormalities. Eosinophil densities were obtained from the
stomach, duodenum, and rectosigmoid areas. Immunohistochemistry (IHC) staining for tumor necrosis factor-α (TNF-α)
and matrix metalloproteinase-9 (MMP-9) was performed on the stomach and rectosigmoid areas.
Results: Gastritis and colonic crypt distortion were present in the IBD group at a greater rate (61 % vs. 22 %, p = 0.020;
34 % vs. 4 %, p = 0.008, respectively). Peak and mean eosinophil densities in the rectosigmoid area were greater in the
IBD group (17.0/hpf vs. 5.0/hpf, p = 0.0063; 12.3/hpf vs. 4.2/hpf, p = 0.0106, respectively). TNF-α and MMP-9 staining did
not reveal any significant differences.
Conclusions: Our data suggests that significantly greater inflammation in the stomach, crypt distortion in the colon,
and eosinophilia in the rectosigmoid distinguished the IBD group from the comparison group at the time of the initial
endoscopic evaluation.
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Background
Diagnosing pediatric inflammatory bowel disease (IBD)
may be challenging at times as a broad spectrum of
gastrointestinal and extra-intestinal symptoms may com-
plicate the clinical presentation. When IBD is suspected,
endoscopy is performed to examine the mucosa and ob-
tain tissue as gross and histologic findings are the gold
standard for diagnosing IBD. Unfortunately, histologic
confirmation cannot always be obtained early in the
course of the disease, thus delaying the diagnosis and
treatment, and ultimately the optimal growth potential
and quality of life for these patients.
While the quality of the histopathologic diagnosis re-
lies heavily on the clinician to provide helpful clinical in-
formation and multiple biopsy specimens from different
sites of the gastrointestinal tract, there are well estab-
lished pathologic criteria for the diagnosis of IBD [1–7].
The typical histologic features of IBD are those of a
chronic active colitis, encompassing chronicity features
of crypt architectural distortion and basal plasmacytosis.
Disease activity is determined by cryptitis, crypt abscesses,
and ulcerations. A variable number of eosinophils may be
present [1]. Ulcerative colitis (UC) demonstrates a grad-
ation of activity indices depending on the acuity of disease
[2, 3]. The inflammatory activity of UC is confined to the
mucosa and submucosa; with extension of disease con-
tinuously and proximally from the rectum. Mucus deple-
tion from goblet cells, cryptitis with crypt abscesses, and
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crypt distortion are findings not unique to UC, but may
also be seen in Crohn’s colitis [4]. In Crohn’s disease (CD),
the inflammation may involve any portion of the gastro-
intestinal tract from the mouth to the anus. The inflam-
matory activity is usually discontinuous with skip lesions
and shows a transmural involvement [5]. Granulomas are
the hallmark lesion of CD but are found in only 40–60 %
of resection specimens and much less frequently
(15–36 %) in mucosal samples [6, 7].
Importantly, 8–31 % of adult patients with UC and
approximately one third of pediatric patients with UC
have presented with absent or atypical findings on
initial biopsies [2, 8, 9]. There is relative paucity of
data addressing this matter specifically in pediatric
CD. Studies regarding the diagnostic lag in children
with IBD are also lacking. Heikenen et al. retrospect-
ively evaluated 91 children diagnosed with IBD, not-
ing that the average lag for diagnosis was 7.1 months
in CD and 6.7 months in UC [10]. Children who pre-
sented with growth failure had the longest diagnostic
lag. A recent study by Kappelman et al. noted that
healthcare utilization by younger IBD patients was
disproportionately increased and costs for IBD pa-
tients younger than 20 were significantly higher than
those for adults, suggesting that effective-management
strategies in this population could yield cost-effective
benefit [11, 12].
Several cytokines and matrix proteins have been impli-
cated in the pathogenesis of IBD. Tumor necrosis factor-
alpha (TNF-α) immunoreactive cells have been noted in
increased frequency in the lamina propria of surgically
resected specimens of patients with CD and UC [13].
Matrix metalloproteinase-9 (MMP-9) has been sug-
gested as a mediator of mucosal breakdown in IBD and
has been shown to be markedly upregulated in intestinal
fistulae specimens of patients with CD [14, 15]. How-
ever, expression of either TNF-α or MMP-9 is not rou-
tinely assessed in the diagnosis of IBD and has not been
studied in the early stages of pediatric IBD.
In our pediatric practice, which includes both a
large volume of patients with IBD and patients with
functional abdominal pain, we have observed that
initial biopsies from children with abdominal pain
who are later diagnosed with IBD may reveal normal
or only subtle non-diagnostic pathologic changes.
We hypothesized that there would be a significant
difference in the presence of certain histologic find-
ings and inflammatory cell types apparent on review
of initial endoscopic biopsies for a subset of diagnos-
tically delayed pediatric IBD patients in comparison
to a group of pediatric abdominal pain patients. We
further hypothesized that IHC staining for TNF-α




Twenty-two IBD patients (11 CD, 10 UC, and 1 indeter-
minate colitis) were identified through a gastroenter-
ology departmental IBD database as subjects who had an
initial inconclusive endoscopy performed from January
2002 to December 2008 prior to a later confirmatory
diagnosis of IBD. Patients who had a definitive diagnosis
of IBD on the initial endoscopy were excluded from the
study. Approximately 650 patients were diagnosed with
IBD during this time period. The comparison group was
comprised of 20 patients with a diagnosis of functional
abdominal pain identified through a gastroenterology
departmental database matched for age, gender, and
study type (EGD, colonoscopy, or both). Patients in this
comparison group underwent endoscopy between Janu-
ary 2003 and December 2004 and were followed for a
time period of at least five years, having not developed
IBD during this time. This study was approved by Chil-
dren’s Mercy Pediatric Institutional Review Board who
waived the need for informed consent due to the retro-
spective nature of the study and analysis of de-identified
data and tissue samples.
Tissue specimens
Biopsy specimens obtained from 37 esophagogastroduo-
denoscopies (EGDs) and 31 colonoscopies were studied.
All biopsies analyzed were obtained during the initial
non-diagnostic endoscopy. The EGD specimens included
multiple grasp biopsies of the distal esophagus, gastric
antrum, and the duodenum. Colonoscopy specimens
were obtained from various areas including terminal
ileum, cecum, ascending colon, transverse colon, de-
scending colon, and rectosigmoid. Release of tissue
samples was approved by the Institutional Review
Board and the Chairman of the Department of Path-
ology at Children’s Mercy Hospital.
Histopathological evaluation
Sections from the biopsy specimens which had been
formalin-fixed and paraffin-embedded in the usual fash-
ion including staining with hematoxylin and eosin were
reviewed by a pediatric pathologist, blinded to diagnostic
group. Specimens were evaluated for the presence of
gastritis, duodenitis, lymphoid hyperplasia, basal plasma-
cytosis, eosinophilia, cryptitis, crypt abscess, and crypt
distortion.
Mucosal (lamina propria) eosinophils of the stomach,
duodenum, and rectosigmoid areas were further quan-
tified by the primary investigator (J.A.B.). Eosinophils
were identified by the characteristic prominent eo-
sinophilic cytoplasmic granules and a typical bi-lobed
nucleus. Densities were determined by counting eosino-
phils in what appeared to be the most involved area after
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scanning the entire specimen. Three consecutive high
power fields (each high power field approximately 0.15
square millimeters at x400 magnification) were evaluated
with the peak count defined as the highest count of the
three fields and the mean count as the average of the three
fields.
Immunohistochemistry
Additional slides were prepared from the gastric antrum
and rectosigmoid biopsy specimens for IHC staining
for tumor necrosis factor-alpha (TNF-α) and matrix
metalloproteinase-9 (MMP-9). Serial 4-μm thick sec-
tions were cut from paraffin embedded tissue blocks
for IHC staining.
IHC staining for TNF-α was performed on the Bond-
MAX automated stainer (Leica Corporation, Melborne,
Australia). The sections were deparaffinized followed by
heat induced antigen retrieval using citrate buffer for
20 min. Mouse monoclonal anti-human TNF-alpha (clone
P/T2:AbCam, Cambridge, MA, USA) was used as the pri-
mary antibody and applied at a 1:400 dilution. The Bond
Polymer Refine Detection kit (Cat. No DS9800 Vision Bio-
Systems BondTM, Newcastle-upon-Tyne, UK) was used
as the detection system and included peroxide block, post
primary enhancer, poly-HRP anti-mouse/rabbit IgG, DAB
chromogen, and hematoxylin counterstain. The stained
sections were evaluated for the presence of TNF-α im-
munoreactive cells and were graded as negative, focal,
or diffuse by a pediatric pathologist. The entire speci-
men was scanned for reactivity. Focal activity was de-
fined as areas of immunoreactive positive cells confined
to 1–2 high power fields. Diffuse activity was defined as
greater than 2 high power fields of involvement by the
immunoreactive cells.
IHC was performed manually for MMP-9. The sec-
tions were deparraffinized and then rehydrated in alco-
hol to tris-buffered saline. Endogenous peroxidase
activity was blocked using 3 % hydrogen peroxide
followed by a protein block with 5 % goat serum. Re-
sidual biotin and avidin activity were quenched using
avidin and biotin block, respectively. Affinity purified
polyclonal, mono specific rabbit anti-human MMP-9
(HPA001238; Sigma-Aldrich, St. Louis, MO, USA) was
used as the primary antibody and applied at a 1:200
dilution overnight at ~4 °C. Labeled streptavidin-
biotin (LSAB) was used for the detection system
with diaminobenzidine tetrahydrochloride (DAB) as
the chromogen. Sections were counterstained with
hematoxylin. The stained sections were evaluated for
the presence of MMP-9 immunoreactive cells and
graded as negative, focal or diffuse by the primary
investigator. The grading scheme was similar to that
followed for TNF-α.
Statistical analysis
Comparisons between groups were made by chi-square
and Fisher’s exact test as appropriate for categorical
variables. Mann–Whitney U test was used to compare
continuous variables. A significance level of p < 0.05 was
established for all statistical comparisons. All calcula-
tions were performed using the SPSS software package
version 17 (SPSS Inc, Chicago, IL).
Results
Patients
Demographic and other patient characteristics are pre-
sented in Table 1. The number of biopsies per site is
presented in Table 2.
Histology
The histologic abnormalities of the study groups are
shown in Table 3. Gastritis (61 % vs. 22 %, p = 0.020)
and crypt distortion in total colonic biopsies (34 % vs.
4 %, p = 0.008) occurred in the IBD group at a signifi-
cantly greater rate than observed in the control group.
In a sub-analysis of the IBD group, the frequency of
gastritis and colonic crypt distortion was not different
between the UC and CD patients. Other architectural
changes and inflammation in individual areas of the
colon, terminal ileum, duodenum, and esophagus did
not significantly differ between the IBD and comparison
group.
Eosinophil counts
Eosinophil counts of study groups are shown in Table 4.
Both peak (17.0/hpf vs. 5.0/hpf, p = 0.0063) and mean
(12.3/hpf vs. 4.2/hpf, p = 0.0106) eosinophil densities in
the rectosigmoid colon were significantly greater in the
IBD group as compared to controls. Gastric and duo-
denal eosinophil densities did not differ significantly be-
tween the two groups. In a sub-analysis of the IBD
group, rectosigmoid eosinophil densities did not differ
between CD and UC patients. Eosinophil densities





Mean age (years) 8.9 9.8
Age range (years) 0–16 0–16
Male/female ratio 0.29 0.33
Diagnosis: Ulcerative Colitis 10 n/a
Crohn’s Disease 11 n/a
Indeterminate Colitis 1 n/a
Mean time from first biopsy to diagnosis
(months)
23.2 n/a
Range of time from first biopsy to
diagnosis (months)
3–72 n/a
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were ≥ 20/hpf in only 4 patients and all 4 subsequently
developed IBD.
Immunohistochemistry
IHC staining for TNF-α and MMP-9, Figs. 1 and 2, re-
spectively, did not differ in the stomach or rectosigmoid
colon for CD vs. UC or IBD vs. controls. For IBD
patients, MMP-9 staining in the stomach was negative
in 83 % and focal in 17 %. Gastric MMP-9 was negative
in all controls. For IBD patients, MMP staining in the
colon was negative in 69 %, focal in 19 %, and diffuse in
13 %. Colonic MMP-9 was negative in 92 % and diffuse
in 8 % of controls. For IBD patients, TNF-α staining in
the stomach was negative in 89 %, focal in 6 %, and dif-
fuse in 6 %. Colonic TNF-α was negative in 94 % and
focal in 6 % of controls. For IBD patients, TNF-α stain-
ing in the colon was negative in 87 %, focal in 7 %, and
diffuse in 7 %. Colonic TNF-α was negative in 92 % and
diffuse in 8 % of controls. The TNF-α immunopositive
cells in the mucosa comprised mostly of macrophages
and occasionally lymphocytes in the lamina propria.
Discussion
Our results demonstrated that initial biopsies in children
with an eventual diagnosis of IBD in comparison to bi-
opsies of children with functional abdominal pain have
significantly greater frequency of inflammation in the
stomach, crypt distortion in the colon, and eosinophilia
in the rectosigmoid area. This study is novel in that the
comparison group is not an adult population but a
pediatric subset of abdominal pain patients. Additionally,
the IBD group has been expanded to include patients
with CD, as prior studies to our knowledge have been
limited to findings in UC [16, 17].
This is one of the first studies to attempt to under-
stand the histologic features associated with the develop-
ment of pediatric IBD. Few studies have addressed the
concern that the initial biopsies of IBD patients may be
negative or inconclusive and these studies have largely
been confined to children with UC [16, 17]. The
pediatric IBD population differs from the adult IBD
population as children with IBD may present with atyp-
ical or normal histologic findings. Markowitz et al. found
that 5 of 12 (42 %) children with ulcerative colitis who
ultimately required colectomy had rectal sparing or mild
patchy inflammation of the rectum and sigmoid areas on
initial biopsy [16]. Another study evaluated 73 pediatric
patients and 38 adult patients, all with newly diagnosed
UC, showing that 30 % of children in comparison with
only 3 % of adults had less severe inflammation in the
rectum compared with more proximal areas [17]. 21 %
Table 2 Number of biopsies by site
Site Total IBD Control
Esophagus 34 17 17
Stomach 36 18 18
Duodenum 37 18 19
Rectosigmoid 29 15 14
Left Colon 5 2 3
Transverse Colon 7 3 4
Right Colon 5 3 2
Cecum 12 8 4
Terminal Ileum 25 14 11
Table 3 Histologic abnormalities of study groups
IBD Control p
value
Gastritis 11/18 (61 %) 4/18 (22 %) .020
Duodenitis 4/18 (22 %) 2/19 (11 %) .303
Lymphoid hyperplasia: duodenum 1/18 (6 %) 0/19 (0 %) .486
Lymphoid hyperplasia: cecum 1/8 (13 %) 0/4 (0 %) .667
Lymphoid hyperplasia: terminal
ileum
3/14 (21 %) 0/11 (0 %) .158
Basal plasmacytosis: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Basal plasmacytosis: transverse
colon
1/3 (33 %) 0/4 (0 %) .429
Basal plasmacytosis: cecum 1/8 (13 %) 0/4 (0 %) .667
Cryptitis: colon any area 6/37 (16 %) 3/33 (9 %) .485
Cryptitis: duodenum 2/18 (11 %) 0/19 (0 %) .230
Cryptitis: rectosigmoid 3/15 (20 %) 1/13 (8 %) .356
Cryptitis: left colon 0/2 (0 %) 1/3 (33 %) .600
Cryptitis: transverse colon 1/3 (33 %) 1/4 (25 %) .714
Cryptitis: right colon 1/3 (33 %) 0/2 (0 %) .600
Cryptitis: terminal ileum 1/14 (7 %) 0/11 (0 %) .560
Crypt abscess: colon any area 2/23 (9 %) 0/18 (0 %) .495
Crypt abscess: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Crypt abscess: cecum 1/8 (13 %) 0/4 (0 %) .667
Crypt distortion: colon any area 10/29 (34 %) 1/24 (4 %) .008
Crypt distortion: rectosigmoid 2/15 (13 %) 0/14 (0 %) .259
Crypt distortion: transverse colon 1/3 (33 %) 0/4 (0 %) .429
Crypt distortion: right colon 2/3 (67 %) 0/2 (0 %) .300
Crypt distortion: cecum 5/8 (63 %) 1/4 (25 %) .273
Table 4 Eosinophil counts of study groups
IBD Control p value
Rectosigmoid mean 12.3 (3.6, 18.6) 4.2 (1.6, 7.0) .0106
Rectosigmoid peak 17.0 (7.0, 24.0) 5.0 (3.0, 10.0) .0063
Stomach mean 2.8 (1.3, 4.6) 1.8 (1.0, 2.6) .3026
Stomach peak 3.5 (2.0, 7.5) 3.0 (2.0, 4.0) .2775
Duodenum mean 8.1 (6.6, 17.3) 8.8 (8.0, 11.0) .9495
Duodenum peak 10.5 (8.5, 20.0) 12.0 (10.0, 15.0) .8488
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of children showed patchy inflammation, which was sig-
nificantly greater than the adults who had none. Wash-
ington et al. demonstrated that chronicity features are
lacking more often on initial rectal biopsies in children
with ulcerative colitis when compared to adults, finding
that the initial biopsies from children were less likely to
show diffuse architectural abnormalities when compared
to adults [9]. In the current study, we demonstrated that
children who will eventually be diagnosed with IBD
demonstrate crypt distortion early in their course more
frequently than children with abdominal pain not associ-
ated with evolving IBD. The presence of crypt distortion
should heighten the clinician’s suspicion of IBD even in
non-diagnostic biopsies.
Upper endoscopy is considered an essential compo-
nent of the initial evaluation of a child with possible IBD
[18, 19]. In a prospective evaluation of the importance of
EGD in the diagnosis of IBD, focally enhanced gastritis
was noted in 11 of 21 cases [19]. Focally enhanced gas-
tritis has been seen more commonly in children with
CD than UC and has also been noted to be present in
76 % of adults with CD compared to 0.8 % of controls
[20, 21]. An increased association of active gastritis in
children with CD has also been noted [22]. The gastritis
noted in our patients was not active or “focally enhanced”
but more indicative of chronic inflammation with a diffuse
increase of lymphoplasmacytic cells in the lamina propria
with or without reactive epithelial changes. The frequency
of gastritis did not differ between CD and UC patients
within the IBD group. As our finding of gastritis is
rather nonspecific, it invites further investigation re-
garding the different types of gastritis noted in early
IBD in children.
In the current study, we demonstrated significantly
higher eosinophil density in the rectosigmoid area of
patients who would eventually be diagnosed with IBD.
Eosinophil infiltration can be nonspecific and may be
observed in conditions such as allergy (e.g. allergy-
associated colitis in adults and allergic proctocolitis in
infants), eosinophilic gastroenteritis, eosinophilic colitis,
IBD, parasite infection, infectious colitis, neoplasm, celiac
disease, and autoimmune diseases [23]. Increased eosino-
phil density has been reported in active inflammation in
both CD and UC and is associated with upregulation of
eosinophil chemoattractants, eotaxin and RANTES [24].
CD is associated with enhanced secretion and accumula-
tion of eosinophil cationic protein released with eosinophil
degranulation [25]. The diagnostic and prognostic values
of tissue eosinophilia in IBD patients, however, remain un-
clear. Some studies have suggested that tissue eosinophilia
in the rectum may be predictive of a more favorable prog-
nosis in UC patients as a paucity of eosinophils has been
noted to be associated with an increased risk of eventual
colectomy [26, 27]. More recent studies, however, have re-
ported a possible dual role for the eosinophil with noted
involvement in tissue destruction and repair in the differ-
ent stages of UC as eosinophils were actually higher in in-
active UC than in the active phase of the disease [28, 29].
Shen et al. found that tissue eosinophilia in ileal pouch
mucosa in IBD patients treated with restorative proc-
tocolectomy was found to be more prominent than
that in the afferent limb, suggesting that luminal fac-
tors in different areas of the bowel may contribute to
eosinophil-mediated inflammation [30]. Our finding of
eosinophilia in the rectosigmoid area of the patients
later diagnosed with IBD in comparison to abdominal
pain patients suggests that eosinophilia may be an
early indicator of disease progression. It should be
noted that we did not control for allergic disease
which may have influenced the results. However, pre-
vious studies have found no association between co-
lonic eosinophil densities and a history of atopy and
no significant seasonal variation [31, 32]. Further in-
vestigation in a prospective manner with a larger
Fig. 1 TNF-α. Example of positive TNF-α stain
Fig. 2 MMP-9. Example of positive MMP-9 stain
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sample size may be warranted to evaluate for the pres-
ence of eosinophils in other areas of the gastrointes-
tinal tract.
Prior studies have shown increased expression of
TNF-α and MMP-9 in IBD tissue specimens [13–15].
The TNF-α immunohistochemistry by Murch et al. was
performed on frozen tissue samples that were not fixed
in formalin or paraffin embedded. We failed to detect a
significant difference in expression of either marker
between the IBD group and the comparison group of ab-
dominal pain patients. This may be due to limited sam-
ple size, timing of disease progression, or technical
limitations of IHC staining on mucosal specimens that
are formalin-fixed and paraffin-embedded. We believe
that IHC on formalin-fixed paraffin embedded tissue is
less sensitive than western blotting and real time PCR
for detecting cytokine expression, however the latter
techniques require fresh or frozen tissue. Future studies
evaluating TNF-α and MMP-9 on fresh or frozen tissue
utilizing western blotting or real time PCR over the
course of disease progression may be helpful in under-
standing the role of TNF-α and MMP-9 as potential
early biomarkers for IBD.
There are several limitations to this study, most im-
portantly, the retrospective nature and limited sample
size. The initial biopsies of approximately 30 % of the
IBD patients included only upper endoscopy specimens.
The addition of colon and terminal ileum biopsies in
those patients may have provided more diagnostic clues.
A prospective design may be challenging as this patient
population is difficult to identify in the early stages of
disease. Although IHC staining for TNF-α and MMP-9
did not provide significant results in this study, further
investigation into other potential IHC markers may be
warranted.
Conclusions
Although typical changes consistent with IBD are present
in most cases, occasionally mucosal biopsies will show
subtle or nonspecific changes. The absence of chronic
changes in the colorectal mucosa on initial biopsies of
some children may delay the diagnosis of IBD and initi-
ation of appropriate medical therapy, thus histopathologic
criteria predicting disease progression in pediatric IBD
may potentially improve patient prognosis and quality of
life. Histopathologic findings of colonic crypt distortion
and possibly rectosigmoid eosinophilia may be early fea-
tures of IBD in children. In such cases, careful observation
should ensue and consideration should be given to repeat
endoscopy if concerning symptoms continue.
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